April 22, 2013
BIND Therapeutics and AstraZeneca Announce Worldwide Development and Commercialization Agreement for Cancer Nanomedicine

 
April 3, 2013
BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins

 
April 3, 2013
Symetis' ACURATE TA(TM) Confirms Superior Results

 
February 28, 2013
CeQur Announces Positive Results from Study Evaluating Simple Insulin Delivery Device Among People with Type 2 Diabetes

 
January 17, 2013
Molecular Partners Announces Publication of Results from a Phase I/II Clinical Trial of its

 
January 8, 2013
BIND Biosciences and Amgen Sign Agreement For The Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine

 
November 27, 2012
CeQur Receives CE Mark for PaQ® Insulin Delivery Device

 
November 12, 2012
Molecular Partners enters into a strategic collaboration agreement with Boehringer Ingelheim to support its proprietary pipeline with clinical supply of DARPin® molecules

 
October 22, 2012
Symetis ACURATE TF™ FIM Trial Completed

 
September 26, 2012
CeQur Completes Study Evaluating Ability of Simple Insulin Delivery Device to Replace Insulin Injections Among People with Type 2 Diabetes

 
September 20, 2012
BIND Is Granted Five U.S. Patents Covering BIND-014 and Accurin(TM) Platform

 
August 21, 2012
Allergan and Molecular Partners Enter into Exclusive Alliance

 
July 25, 2012
Nfocus Neuromedical, Inc. Announces Positive One-Year Follow-Up Results from Clinical Study of Luna(TM) Aneurysm Embolization System

 
July 16, 2012
BIND Biosciences appoints Andrew J. Hirsch as Chief Financial Officer

 
June 22, 2012
BIND Biosciences CEO Scott Minick and Founder Omid Farokhzad Win Ernst & Young New England Entrepreneur of the Year Award

 
June 16, 2012
Clinical Study begins on Insulin Delivery Device for Type 2s

 
June 15, 2012
OncoEthix In-Licenses OTX015, an anticancer Bromodomain inhibitor from Mitsubishi Tanabe Pharma Corporation

 
May 31, 2012
Molecular Partners AG strengthens management team with the appointment of Lisa Rojkjaer, MD as Chief Medical Officer

 
May 15, 2012
PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System

 
April 4, 2012
BIND Biosciences Presents Clinical Data on BIND-014 Promising Anti-tumor Effects in Patients with Advanced or Metastatic Cancers

 
January 27, 2012
Daniel Bertholet of Endeavour Vision speaks at SECA event

 
December 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
October 27, 2011
BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline

 
September 30, 2011
Symetis’ ACURATE TA™ Aortic Bioprosthesis Receives CE Mark Certification on Sept. 30th 2011

 
May 18, 2011
Symetis reports on its trans-apical ACURATE TA™ clinical

 
May 4, 2011
Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

 
April 28, 2011
Molecular Partners reports positive results from its first clinical studies

 
April 6, 2011
BIND Biosciences Receives 2011 Edison Award

 
February 23, 2011
BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row

 
February 15, 2011
Nfocus Neuromedical, Inc. Luna™ Aneurysm Embolization System Receives CE Mark

 
February 11, 2011
BIND Biosciences featured in the London Times

 
February 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
January 7, 2011
BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014

 
January 4, 2011
PneumRx, Inc. Raises $33 Million in Capital

 
April 13, 2010
CeQur SA names Robert O'Holla EVP for Regulatory Affairs

 
Luna devices have demonstrated stability up to one year post-implantation

PALO ALTO, Calif., July 25, 2012 - Nfocus Neuromedical, Inc., an innovative medical device company with a focus on the next generation treatment for brain aneurysms, announced today positive data from an ongoing clinical study of the company's Luna(TM) Aneurysm Embolization System (AES). Michel Piotin, MD, PhD, of the Foundation Rothschild, Paris, presented the data today at the Society for Neurointerventional Surgery (SNIS) Annual Meeting in San Diego, Ca.

According to the initial one-year follow-up results from the ongoing EU clinical study, implanted Luna devices have remained stable up to one year, a critical inflection point to measure success of a new technology. Clinical experience has also demonstrated that the Luna AES can be delivered quickly (within 15 minutes) to locations where the majority of aneurysms occur and to a wide variety of aneurysm types.

"I am pleased ...

more...
© Endeavour Vision SA 2006-2013 Terms & Conditions